Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer - 22/03/24
Abstract |
Bladder cancer (BC) is a common malignant tumor of urinary system, which can be divided into muscle-invasive BC (MIBC) and nonmuscle-invasive BC (NMIBC). The number of BC patients has been gradually increasing currently. At present, bladder tumours are diagnosed and followed-up using a combination of cystoscopic examination, cytology and histology. However, the detection of early grade tumors, which is much easier to treat effectively than advanced stage disease, is still insufficient. It frequently recurs and can progress when not expeditiously diagnosed and monitored following initial therapy for NMIBC. Treatment strategies are totally different for different stage diseases. Therefore, it is of great practical significance to study new biomarkers for diagnosis and prognosis. In this review, we summarize the current state of biomarker development in BC diagnosis and prognosis prediction. We retrospectively analyse eight diagnostic biomarkers and eight prognostic biomarkers, in which CK, P53, PPARγ, PTEN and ncRNA are emphasized for discussion. Eight molecular subtype systems are also identified. Clinical translation of biomarkers for diagnosis, prognosis, monitoring and treatment will hopefully improve outcomes for patients. These potential biomarkers provide an opportunity to diagnose tumors earlier and with greater accuracy, and help identify those patients most at risk of disease recurrence.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Multiple molecular markers are combined to improve the accuracy of bladder cancer in diagnosis and prognosis. |
• | Except for the diagnosis and prognosis, personalized treatments such as immune checkpoint inhibitors have also been added. |
• | We summarize the molecular typing based therapies for muscle-invasive bladder cancer using a multi-layer pie charts. |
• | We summarize the regulatory network of P53-PPARγ-PTEN in BC proliferation using concise illustrations. |
Keywords : Bladder cancer, Molecular biomarkers, Molecular subtyping, Diagnosis, Prognosis
Plan
Vol 173
Article 116312- avril 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?